MAPK
MAPKs are a family of protein kinases involved in a variety of cellular processes, including growth, proliferation, differentiation, and stress responses. The MAPK signaling pathway consists of several tiers, including ERK, JNK, and p38 MAPKs, each playing distinct roles in cellular function. Dysregulation of MAPK signaling is linked to cancer, inflammatory diseases, and metabolic disorders. At CymitQuimica, we offer a wide array of MAPK inhibitors and activators to support your research in cell biology, signal transduction, and disease mechanisms.
Found 897 products of "MAPK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Sosimerasib
CAS:Sosimerasib is an inhibitor of the kirsten rat sarcoma viral oncogene homolog (KRAS) and exhibits antitumor activity.Formula:C36H39ClFN7O4Color and Shape:SolidMolecular weight:688.191MRTX849 ethoxypropanoic acid
CAS:MRTX849 is a KRAS G12C ligand and PROTAC linker for creating potent LC-2, degrading KRAS G12C with DC50 of 0.25-0.76 μM.Formula:C37H43ClFN7O5Color and Shape:SolidMolecular weight:720.24KRAS G12D inhibitor 12
KRAS G12D inhibitor 12 targets Ras protein for cancer research. (Patent WO2021108683A1, Compound 134)Formula:C23H21ClFN5O3Color and Shape:SolidMolecular weight:469.9OZO-H
CAS:OZO-H is a GST inhibitor and a potent anticancer derivative of OZO. It releases JNK1 from the GST-JNK1 complex, induces JNK1 phosphorylation, and activates c-Jun in cancer cells.Formula:C8H5NO2SColor and Shape:SolidMolecular weight:179.20Dioleyl phosphatidylserine
CAS:Dioleyl phosphatidylserine is a phospholipid that can activate PKC-γ (Protein Kinase C-gamma) when the Ca2+ concentration is below 0.5 μM, specifically at a concentration of 100 μM.Formula:C42H78NO10PColor and Shape:SolidMolecular weight:788.04Nek2/Hec1-IN-3
CAS:Nek2/Hec1-IN-3 (Compound 11-28) is an inhibitor of the Hec1/Nek2 interaction. It disrupts the binding between Nek2 and Hec1 and is applicable for research in tumor diseases.Formula:C16H13N3OSColor and Shape:SolidMolecular weight:295.36SML-10-70-1
CAS:SML-10-70-1 is a Novel Active Site Inhibitor of Oncogenic K-Ras G12C.Formula:C25H42ClN7O13P2Color and Shape:SolidMolecular weight:746.04Dorrigocin A
CAS:Dorrigocin A, an analog of Migrastatin, inhibits the carboxymethyltransferase involved in Ras processing, reversing the morphology of Ras-transformed NIH/3T3 cells. Dorrigocin A holds potential for research as an anticancer and anti-arthritis agent.Formula:C27H41NO8Color and Shape:SolidMolecular weight:507.616pan-Raf/RTK inhibitor 1
CAS:Pan-Raf/RTK inhibitor 1 (compound I-16) is a potent pan-Raf inhibitor with IC50 values of 3.49 nM (BRafV600E), 8.86 nM (ARaf), 5.78 nM (BRafWT), and 1.65 nM (CRaf). It exhibits antiproliferative activity against various cancer cell lines and can be utilized in cancer research.Formula:C29H28F3N7O3Color and Shape:SolidMolecular weight:579.573SOF-436
CAS:SOF-436 is a KRAS inhibitor that can suppress SOS1-mediated KRAS nucleotide exchange (IC50 = 60 μM) and inhibit the interaction between KRAS and the effector protein RAF. SOF-436 is applicable to cancer research.Formula:C15H13F2NO4S2Color and Shape:SolidMolecular weight:373.395JAK3-IN-13
JAK3-IN-13: Oral JAK3 inhibitor, selective & potent. Acts on NK1, JNK2, JNK3, Tyk2. Anti-tumor. IC50: JNK3, 8 nM; Tyk2, 365 nM; JNK2, 2039 nM; NK1, 4728 nM.Formula:C25H33ClN6O5Color and Shape:SolidMolecular weight:533.02HPK1-IN-14
CAS:HPK1-IN-14 is a potent inhibitor of HPK1. HPK1-IN-14 has potential for the study of HPK1-related diseases.Formula:C24H23FN6O2Color and Shape:SolidMolecular weight:446.48SOS1-IN-10
SOS1-IN-10 is a potent inhibitor of SOS1 that acts on KRAS G12C-SOS1 (IC50: 13 nM).Formula:C22H19F5N4OColor and Shape:SolidMolecular weight:450.4KRAS G12D inhibitor 1
CAS:KRAS G12D inhibitor 1 (example 243) is an inhibitor of KRAS G12D with an IC 50 of 0.8 nM for KRAS G12D-mediated ERK phosphorylation [1].Formula:C33H32F2N6O2Color and Shape:SolidMolecular weight:582.64p38-α MAPK-IN-5
CAS:p38-α MAPK-IN-5: potent p38α inhibitor, IC50s: 0.1 nM (α), 0.2 nM (β), 944 nM (γ), 4100 nM (δ); anti-inflammatory, promising for asthma/COPD research.Formula:C37H49N11O2Color and Shape:SolidMolecular weight:679.86LSN3074753
CAS:LSN3074753, a derivative of LY3009120, acts as a pan-RAF and Raf dimer inhibitor. This compound exhibits inhibitory activity against tumor cells driven by either BRAF monomers or RAF dimers, particularly in the activation of the MAPK pathway, including colorectal cancers with BRAF or KRAS mutations. When combined with Cetuximab, LSN3074753 demonstrates additive and synergistic effects in colorectal cancer PDX models, especially in those harboring KRAS or BRAF mutations.Formula:C24H30FN5O2Color and Shape:SolidMolecular weight:439.53KRAS inhibitor-27
CAS:KRAS inhibitor-27 (Compound 15h) is a KRAS inhibitor that effectively targets KRAS G12D/G12V mutated cells (AsPC-1 and SW620) and wild-type KRAS cells (HT-29), with IC50 values of 378 nM, 0.6 nM, and 3230 nM, respectively. It reduces ERK phosphorylation, with IC50 values of 0.6 nM and 1 nM in AsPC-1 and SW620 cells, respectively, and decreases DUSP4 expression, thereby inhibiting the MAPK signaling pathway.Formula:C31H28ClF3N6O3SColor and Shape:SolidMolecular weight:657.106p38α-MK2-IN-1
CAS:p38α-MK2-IN-1 (Compound 36) is an inhibitor of the p38α-MK2 complex, with an IC50 of 5 nM. This compound exhibits significant anti-inflammatory properties and has the ability to aid in joint repair.Formula:C27H26F3N5O3Color and Shape:SolidMolecular weight:525.522KRAS inhibitor-8
CAS:KRAS inhibitor-8 is a potent KRAS G12C inhibitor.Formula:C26H24ClF4N5O3Purity:98%Color and Shape:SolidMolecular weight:565.95RGT-018
CAS:RGT-018 is a potent oral SOS1 inhibitor with antitumor properties. It exerts its anticancer activity by inhibiting KRAS activation, thereby hindering cancer cell proliferation.Formula:C27H24F3N7O2Color and Shape:SolidMolecular weight:535.52
